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Comorbid Conditions in idiopathic 
Pulmonary Fibrosis: Recognition  
and Management
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1 Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California at Davis, Davis, 
CA, United States, 2 Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California at 
San Francisco, San Francisco, CA, United States
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, 
primarily affects older adults and leads to a progressive decline in lung function and 
quality of life. With a median survival of 3–5 years, IPF is the most common and deadly 
of the idiopathic interstitial pneumonias. Despite the poor survivorship, there exists 
substantial variation in disease progression, making accurate prognostication difficult. 
Lung transplantation remains the sole curative intervention in IPF, but two anti-fibrotic 
therapies were recently shown to slow pulmonary function decline and are now approved 
for the treatment of IPF in many countries around the world. While the approval of these 
therapies represents an important first step in combatting of this devastating disease, a 
comprehensive approach to diagnosing and treating patients with IPF remains critically 
important. Included in this comprehensive assessment is the recognition and appropri-
ate management of comorbid conditions. Though IPF is characterized by single organ 
involvement, many comorbid conditions occur within other organ systems. Common car-
diovascular processes include coronary artery disease and pulmonary hypertension (PH), 
while gastroesophageal reflux and hiatal hernia are the most commonly encountered 
gastrointestinal disorders. Hematologic abnormalities appear to place patients with 
IPF at increased risk of venous thromboembolism, while diabetes mellitus (DM) and 
hypothyroidism are prevalent metabolic disorders. Several pulmonary comorbidities 
have also been linked to IPF, and include emphysema, lung cancer, and obstructive 
sleep apnea. While the treatment of some comorbid conditions, such as CAD, DM, 
and hypothyroidism is recommended irrespective of IPF, the benefit of treating others, 
such as gastroesophageal reflux and PH, remains unclear. In this review, we highlight 
common comorbid conditions encountered in IPF, discuss disease-specific diagnostic 
modalities, and review the current state of treatment data for several key comorbidities.
Keywords: idiopathic pulmonary fibrosis, idiopathic interstitial pneumonia, interstitial lung disease, pulmonary 
fibrosis, co-morbidity
iNTRODUCTiON
Idiopathic Pulmonary Fibrosis (IPF), a fibrosing interstitial lung disease (ILD) of unknown etiology, 
primarily affects older adults and leads to a progressive decline in lung function and quality of life 
(1–4). With an estimated prevalence of 18–63 cases per 100,000 and median survival of 3–5 years 
(5, 6), IPF remains the most common and deadly of the idiopathic interstitial pneumonias (IIPs). 
FigURe 1 | High-resolution computed tomography findings in a patient, 
with combined pulmonary fibrosis and emphysema. Centrilobular 
emphysema is observed on apical views (A) and basilar predominant 
sub-pleural reticulation and honeycombing characteristic of UIP is observed 
on basilar views (B).
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Despite poor survivorship, there exists substantial variability in 
disease progression, whereby most patients experience a steady 
clinical decline, some remain stable over many years and others 
die from rapidly progressive disease (3, 7, 8). Lung transplanta-
tion remains the sole curative intervention for IPF, but two 
anti-fibrotic therapies were recently shown to slow pulmonary 
function decline in phase III clinical trials (9–11). Post hoc analy-
ses of clinical trial datasets also suggest that anti-fibrotic therapy 
may reduce the risk of acute exacerbations and improve overall 
survival in those with IPF (12–14).
While the identification of therapies that effectively slow IPF 
progression represents a monumental step forward in the care of 
patients with IPF, pharmacotherapy is but one component of the 
multi-pronged approach necessary to optimally manage patients 
with IPF. Other equally important pieces include evidence-based 
prognostication (15) improvement of functional status with for-
mal pulmonary rehabilitation and supplemental oxygen (where 
appropriate), patient education with regard to IPF pathobiology, 
natural history, and clinical trial availability, and management of 
common comorbidities (4, 16). In this review, we highlight com-
mon comorbidities encountered in IPF, discuss diagnostic and 
screening modalities, and review the current state of treatment 
data for such conditions.
PULMONARY COMORBiDiTieS
emphysema
Roughly 70–80% of individuals with IPF endorse a history of 
cigarette smoking, which has long been an established IPF risk 
factor (17–20). Not surprisingly, about 30% of IPF patients have 
concurrent pulmonary emphysema (21, 22), including 8–27% 
with ≥10% emphysematous involvement throughout the lungs 
(Figure 1) (22, 23). The syndrome of combined pulmonary fibro-
sis and emphysema (CPFE) has recently gained recognition as a 
potentially unique IPF phenotype (24). Individuals with CPFE 
tend to be males with an extensive smoking history and increased 
oxygen requirement (21–24). Pulmonary function testing in these 
individuals often shows relatively preserved total lung capacity 
and forced vital capacity (FVC), with a disproportionate reduc-
tion in diffusion capacity (DLCO) (Figure 2) (21, 22, 24). These 
physiologic hallmarks of CPFE likely reflect the opposing impact 
of parenchymal fibrosis and parenchymal destruction on airflow 
and lung volumes, along with additive impact on gas exchange.
High-resolution computed tomography (HRCT) is part of the 
routine diagnostic evaluation of all patients with suspected IPF 
(4), and routine semi-quantitative assessment of emphysematous 
involvement may help readily identify those with CPFE once a 
diagnostic consensus is established. The recognition of CPFE has 
potential management implications. Some studies suggest that 
CPFE is associated with reduced survival (21, 23, 25), but oth-
ers have not replicated this observation (22, 26). Paradoxically, 
patients with CPFE appear to have a slower rate of FVC decline, 
perhaps due to the impact of emphysema on the manner in which 
FVC reflects progressive fibrosis (27). An increased prevalence 
of pulmonary hypertension (PH) has also been demonstrated 
among those with CPFE (22, 23), which may also impact survival 
(23, 24). Treatment of patients with IPF and CPFE with inhaled 
long-acting anti-cholinergic, inhaled long-acting beta-agonist 
and/or inhaled corticosteroids is of unclear benefit (21, 24). 
We believe that clinicians should consider the addition of these 
therapies according to chronic obstructive pulmonary disease 
consensus guidelines (28).
Lung Cancer
Compared to those in the general population, individuals with 
IPF have a nearly 5-fold increased risk of developing lung cancer, 
with 3–22% of patients affected and an estimated incidence of 11 
cases per 100,000 person-years (29–32). The annual lung cancer 
risk also appears to rise in the years following IPF diagnosis 
(32), which was supported by an autopsy study that identified 
concurrent pulmonary malignancy in nearly 50% of cases with 
histologic UIP (33). The strong link between IPF and cigarette 
smoking history (17) likely explains a portion of the increased 
lung cancer risk, as the overwhelming majority of patients with 
IPF who develop lung cancer endorse such a history (32–34). 
The higher prevalence of lung cancer among those with CPFE 
compared to lone IPF also supports this observation (34–36). 
FigURe 2 | Pulmonary function testing in a patient with combined pulmonary fibrosis and emphysema. Flow volume loop (A) shows mild obstructive morphology, 
but normal spirometry (B). Lung volumes (B) are normal. Diffusion capacity (B) is markedly reduced.
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Most studies show squamous cell carcinoma to slightly predomi-
nate over adenocarcinoma (37), while a recent investigation of 
IPF-related adenocarcinomas demonstrated a high frequency of 
bronchiole-associated markers in IPF cases compared to non-IPF 
controls, suggesting that these tumors may arise from abnormally 
proliferating bronchioles in areas of honeycomb cyst (38).
Survival among those with IPF and comorbid lung cancer is 
poor (34, 39) and often stems from malignancy-related clinical 
deterioration, as similar rates of pulmonary function decline 
have been demonstrated in those with and without comorbid 
lung cancer (34). While surgical resection of early stage lung 
cancer may be curative, IPF severity and disease trajectory must 
be taken into consideration, given an increased risk of postop-
erative morbidity and mortality (40, 41). Surgical resection of 
lung cancer appears to increase the risk of acute exacerbation in 
patients with IPF, which has been reported in 7–32% of patients 
(42–45). Acute exacerbation and clinical deterioration have also 
been described in patients with IPF undergoing treatment with 
chemotherapy (46, 47) and radiation therapy (48), underscoring 
the importance of patient education and risk/benefit analysis in 
those with inoperable lung cancer. Recent studies suggest that the 
anti-proliferative effects of pirfenidone and nintedanib may syn-
ergize with current chemotherapeutic regimens, but additional 
research is needed (37, 49, 50).
As for emphysema, HRCT serves as a reasonable modality for 
lung cancer screening, but many HRCT protocols still perform 
non-contiguous imaging, which can miss early nodules and other 
local changes; contiguous imaging is required (4). Most lung 
cancers identified are incidental, with a large minority having 
a potential surgical cure (34, 39). As such, we believe clinicians 
should consider annual lung cancer screening with low-dose 
computed tomography (51) in high-risk patients with IPF, 
including those with CPFE and/or longstanding smoking history. 
Clinicians should also maintain a low threshold for repeat imag-
ing in those who experience clinical worsening despite stable 
pulmonary function or develop symptoms atypical for IPF.
Obstructive Sleep Apnea (OSA)
Preliminary studies suggest that OSA may be an underappreci-
ated comorbid condition in those with IPF. Three investigations 
have shown OSA to be present in 58–88% of patients with IPF, 
with up to 68% having moderate-to-severe OSA based on an 
apnea–hypopnea index ≥15 events/hour (52–54). In addition, 
severe sleep apnea was recently shown to be strongly associated 
with ischemic heart disease in patients with IPF (54). Despite 
this potential high prevalence, few IPF patients are evaluated for 
OSA. A retrospective investigation of IPF patients showed that 
less than 3% of patients were referred for polysomnography (55). 
Untreated OSA can result in nocturnal hypoxemia, the presence 
of which was recently shown to predict worsened survival in 
patients with IPF (56). Nocturnal hypoxemia strongly correlates 
with an increased right ventricular systolic pressure (RVSP) (56), 
which may reflect PH (57).
As with the general population, moderate-to-severe OSA 
is generally treated with continuous positive airway pressure 
(CPAP). CPAP initiation has been shown to improve quality of 
life measures and sleep instruments in those with IPF and comor-
bid moderate-to-severe OSA, though CPAP non-adherence was 
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common (58). The optimal tool for OSA screening in patients 
with IPF has yet to be determined, as commonly utilized OSA 
screening tools, including the Epworth sleepiness scale and Sleep 
Apnea Scale for Sleep Disorders Questionnaire, did not differen-
tiate IPF patients with and without OSA in a recent prospective 
investigation (52). Until an effective screening tool is established, 
clinicians should maintain a low threshold for polysomnography 
referral in patients with IPF.
CARDiOvASCULAR COMORBiDiTieS
Coronary Artery Disease (CAD)
Idiopathic pulmonary fibrosis and CAD share several risk fac-
tors, including increasing age, male gender, and smoking history. 
Among the largest retrospective studies conducted to date, the 
estimated prevalence of CAD in those with IPF ranges from 4 to 
25% (59–63). A prevalence of up to 68% was described in a cohort 
of 73 IPF patients who underwent cardiac catheterization as part 
of a lung transplant work-up (64). Among these individuals, 
18% of patients had significant CAD, defined as >50% stenosis 
of a major coronary vessel on cardiac catheterization or need 
for percutaneous coronary intervention. Longitudinal analyses 
have suggested that 7% of patients will develop CAD in the years 
following IPF diagnosis (63) and that such patients have a 3-fold 
higher risk of experiencing acute coronary syndrome compared 
to non-IPF control subjects (61).
The U.S. Preventative Services Task Force concluded that 
there was insufficient evidence to recommend for or against 
routine CAD screening in asymptomatic, high-risk individuals 
in the general population (65). Among symptomatic patients, the 
American Heart Association suggests that cardiac CT may be a 
reasonable modality for CAD screening, as the presence of coro-
nary calcifications is a reliable predictor of CAD (66). Because 
HRCT is recommended for all patients with IPF, the assessment of 
coronary artery calcification may provide a reliable tool for non-
invasive CAD screening in this high-risk population. A study of 57 
patients with IPF who underwent cardiac catheterization showed 
that the presence of moderate-to-severe coronary calcifications 
had a sensitivity and specificity of >80% for detecting CAD (67). 
Because significant CAD has been associated with worse survival 
in patients with IPF (64), clinicians should consider a cardiology 
referral in patients with angina or moderate-to-severe coronary 
calcifications on HRCT.
Pulmonary Hypertension
Pulmonary hypertension defined as mean pulmonary artery 
pressure (mPAP) ≥25 mm Hg (68), commonly complicates IPF, 
especially as the disease progresses. The true prevalence of PH in 
those with IPF is difficult to ascertain, as estimates vary widely 
based on case finding methodology and the IPF population under 
consideration. A PH prevalence as low as 3% has been reported 
in patients with IPF using insurance claims data (62) and as high 
as 84% using transthoracic echocardiogram (TTE) (69). A preva-
lence of 29–46% has been reported in studies utilizing right heart 
catheterization, which remains the gold standard for PH detection 
(60, 68, 70–75). However, these studies may overestimate the true 
prevalence, as the majority of patients included in these studies 
underwent right heart catheterization as part of a lung transplant 
evaluation, suggesting that many had advanced disease.
Pulmonary hypertension should be suspected in patients with 
dyspnea or oxygen desaturation out of proportion to pulmonary 
function, disproportionately low DLCO, evidence of right heart 
failure on physical exam, or evidence of pulmonary artery 
enlargement and/or right ventricular hypertrophy on imaging 
studies. TTE, which estimates RVSP as a surrogate for mPAP, 
is perhaps the most commonly utilized modality to screen for 
PH. Although TTE-estimated RVSP has been shown to correlate 
poorly with mPAP determined by right heart catheterization 
(73, 76), an RVSP >35 mm Hg has been shown to have a sensitivity 
of >85% for detecting PH in patients with IPF (73). Unfortunately, 
the specificity of this RVSP cut-off is only 29%, so clinicians should 
expect a large number of false positives if using this threshold 
for triggering right heart catheterization. The decision to refer a 
patient for cardiac catheterization when TTE suggests the pres-
ence of PH should be made on a case-by-case basis.
There are currently no approved therapies for the treatment of 
PH in patients with IPF and the last decade has seen a disappoint-
ing number of negative clinical trials using vasodilator therapies. 
Several studies have investigated the use of PH therapies for IPF 
in general (regardless of the presence of PH) and failed to dem-
onstrate efficacy in slowing IPF progression (77–79), and did not 
alter cardiovascular hemodynamics in those with concurrent PH 
(80, 81). A small trial of ambrisentan in patients with IPF and 
right heart catheterization-proven PH (NCT00879229) was 
stopped after a parent trial of ambrisentan showed no benefit in 
the subgroup of IPF patients with known PH (78). A similar trial 
of riociguat (NCT02138825), a soluble guanylate cyclase stimula-
tor, was also terminated after interim analysis showed that those 
in the intervention arm had an increased risk of death and other 
serious adverse events.
The phosphodiesterase-5 inhibitor sildenafil was studied 
in patients with advanced IPF (defined by a baseline DLCO of 
less than 35%). While it did not significantly alter the primary 
functional endpoint of walk distance, it did show improve-
ments in dyspnea score, oxygenation, and quality of life (82). 
A post hoc subgroup analysis of patients with evidence of PH by 
TTE showed that sildenafil therapy did improve walk distance 
as well (83). Based on these data, clinical trials investigating 
sildenafil in combination with anti-fibrotic therapy for patients 
with IPF-associated PH (NCT02951429, NCT02802345) are 
currently enrolling. The most recent evidence-based guidelines 
conditionally recommend against the routine use of sildenafil in 
patients with IPF until randomized controlled trials provide more 
definitive data (16).
Pulmonary embolism (Pe)/venous 
Thromboembolism (vTe)
Relatively few studies have assessed the epidemiology and clinical 
consequences of PE and more broadly VTE in patients with IPF. 
A study utilizing U.S. insurance claims data suggested that 2.7% 
of individuals with a diagnosis code for IPF also carried a diagno-
sis of PE (62). Another U.S. insurance claims-based investigation 
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showed that among decedents with a diagnosis of IPF, 1.7% had 
concurrent VTE (84). These estimates were supported by a case–
control analysis conducted in the U.K., which reported a VTE 
prevalence of 2% in their IPF population, which was 2-fold higher 
than that observed among non-IPF control subjects (61). Danish 
investigators showed that individuals previously diagnosed with a 
VTE were at increased risk of developing incident IIP, suggesting 
that VTE may be a risk factor for IPF and other IIPs (85).
Longitudinal analyses of patients with IPF suggest that the 
risk of incident VTE is 3–6 times higher among patients with IPF 
compared to control subjects, with an estimated 6–9 new events 
per 1,000 person-years (61, 86). As such, clinicians should main-
tain a low threshold for PE evaluation in patients with progressive 
symptoms in the setting of stable pulmonary function metrics. 
PE should also be excluded in patients with acute or subacute 
clinical worsening, as this often indicates an acute exacerbation 
(87). A multi-phase HRCT with and without contrast enhance-
ment should be considered to optimally assess the pulmonary 
vasculature and parenchyma. Lower extremity duplex ultrasound 
can be considered for patients with a contrast allergy and in those 
too unstable to undergo HRCT.
The treatment of PE/VTE requires prolonged blockade 
of the coagulation cascade, which facilitates clot resolution. 
The American College of Chest Physicians recommend 3 months 
of anticoagulant therapy in those with VTE provoked by surgery 
or other known VTE risk factor. These guidelines also recommend 
at least 3 months of anticoagulant therapy in patients with a first-
time unprovoked VTE, after which time the risk–benefit ratio for 
extended therapy should be considered (88). This assessment is 
of particular importance in patients with IPF, as warfarin therapy 
was shown to increase the risk of death in a general population 
of IPF patients (excluding those who required anticoagulation 
for a non-IPF indication) (89). Warfarin therapy has also been 
linked to worse outcomes in uncontrolled studies, including a 
recent post hoc analysis of IPF clinical trial datasets (90, 91). These 
findings raise the question of whether warfarin therapy should 
be used in patients with IPF who require anticoagulation for 
comorbid diseases (e.g. PE, atrial fibrillation). More research is 
needed to determine the optimal therapy and duration of therapy 
for patients with IPF with an indication for anticoagulation.
gASTROiNTeSTiNAL COMORBiDiTieS
gastro-esophageal Reflux (geR)
Gastro-esophageal reflux is another common comorbid 
condition in patients with IPF (92), but the true prevalence of 
GER in patients with IPF is difficult to ascertain. Several large 
epidemiological studies have suggested a prevalence of 30–50% 
(19, 93, 94), but studies that utilized esophageal pH monitoring 
suggest that GER may affect over 80% of individuals with IPF 
(95, 96). Complicating estimates further is the fact that some 
individuals have silent GER (95) and other primarily non-acid 
GER (97).
The ideal modality for diagnosing GER remains unclear. While 
all patients should be screened for GER-associated symptoms, 
including heartburn, choking, and regurgitation, symptom-based 
screening has a low sensitivity for detecting pathologic GER 
(95, 98). Fluoroscopic barium swallow testing can detect GER 
and microaspiration, but this also suffers from poor sensitivity 
(99, 100). Gastro-esophageal scintigraphy can detect GER with 
80% sensitivity but is not a widely available (101). Esophageal 
pH monitoring remains the gold standard for diagnosing acid 
GER, with a reported sensitivity and specificity of over 80% 
(102, 103). Recent studies suggest that multi-channel intralumi-
nal esophageal impedance testing may be a superior modality for 
detecting both acid and non-acid GER, but this modality is not 
widely available at present (103, 104).
It has been hypothesized that GER may contribute to the 
progression of IPF in some patients. Several studies, with mixed 
results, have explored the influence of anti-acid therapy on IPF 
disease course. GER therapy was associated with improved 
survival in a retrospective, multi-center cohort analysis (19) and 
less pulmonary function decline in a post hoc analysis of three 
clinical trial datasets (105). These findings were not replicated in 
a recent post hoc analysis of a separate clinical trial dataset (106). 
Additional data evaluating the efficacy of both medical and surgi-
cal GER therapy in patients with IPF are expected in the near 
future as two phase II clinical trials are underway (NC02085018; 
NCT01982968).
Hiatal Hernia (HH)
A likely contributor to the high prevalence of GER in patients 
with IPF is HH, which has been described in 40–53% of patients 
with IPF (107, 108). While an increasing degree of HH is likely to 
result in GER symptoms, mild HH can be asymptomatic (108). 
HH can be identified on HRCT mediastinal views and does 
not require dedicated imaging. HH treatment largely focuses 
on GER-associated symptom control, but surgical correction 
should be considered in patients with refractory symptoms. 
A retrospective investigation of patients awaiting lung transplan-
tation showed that Nissen fundoplication was well tolerated and 
was associated with stabilization of oxygen levels in this patient 
population (109).
eNDOCRiNe/MeTABOLiC 
COMORBiDiTieS
Hypothyroidism
While 1–2% of men and 5–9% of women in the general popula-
tion carry a diagnosis of hypothyroidism (110–112), a recent 
case–control analysis demonstrated a substantially higher preva-
lence among individuals with IPF, with 13% of men and 28% of 
women affected (20). Furthermore, those with combined IPF and 
hypothyroidism had reduced survival compared to those with 
IPF alone. The biology underpinning an increased prevalence 
of hypothyroidism in IPF remains unclear, but because autoim-
mune thyroiditis is the most common cause of hypothyroidism 
in developed nations (110–112), aberrant immune activation in 
IPF may play a role.
Diabetes Mellitus (DM)
Case–control analyses performed in Japan, Mexico, and the U.K. 
estimated the prevalence of DM type 2 to be 10–33%, among 
TABLe 1 | Common comorbidities in patients with idiopathic pulmonary fibrosis.
Comorbidity Prevalence 
(%)
Outcome association
Emphysema 8–34 Mixed results; may increase mortality 
risk
Increased prevalence of pulmonary 
hypertension (PH)
Lung cancer 3–22 Increased mortality risk
Surgical resection may increase 
mortality and acute exacerbation risk
Chemotherapy may increase acute 
exacerbation risk
Obstructive sleep apnea 58–88 May increase mortality risk through 
worsening nocturnal hypoxemia
Coronary artery disease 4–68 May increase mortality risk
PH 3–84 Increases mortality risk
Pulmonary 
embolism/venous 
thromboembolism
2–3 Treatment with anti-coagulation may 
increase mortality risk
Gastro-esophageal 
reflux
30–80 Mixed results; treatment with antacid 
therapy may improve survival and 
reduce disease progression
Hiatal hernia 40–53 Surgical correction may improve 
survival and stabilize oxygenation in 
patients awaiting transplant
Hypothyroidism 13–28 May increase mortality risk
Diabetes mellitus type 2 10–33 Unknown
Depression 12–49 Unknown
Anxiety 10 Unknown
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CONCLUSiON
Idiopathic pulmonary fibrosis remains a devastating diagnosis for 
patients and their families, and its management requires a multi-
pronged approach. Comorbidity assessment and management 
is a cornerstone of comprehensive management of IPF and we 
have reviewed the most commonly associated comorbidities that 
clinicians should consider (Table 1). Aggressive management of 
comorbidities is promoted by IPF centers of excellence across the 
country and may explain some of the improved survival associ-
ated with these centers (118). We strongly believe that proper 
comorbidity assessment and management can improve quality of 
life and has the potential to improve patient survival in IPF.
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